Reviving Lonidamine and 6-diazo-5-oxo-l-norleucine to be used in combination for metabolic cancer therapy

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  Cervantes Madrid, Diana ^a   Romero, Yair ^b   Dueñas González, Alfonso ^b  

^a INSTITUTO NACIONAL DE CANCEROLOGÍA   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

6 DIAZO 5 OXONORLEUCINE; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; LONIDAMINE; ANTINEOPLASTIC AGENT; INDAZOLE DERIVATIVE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMINO ACID METABOLISM; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; BLURRED VISION; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CONFUSION; DIARRHEA; DROWSINESS; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; EPIGASTRIC PAIN; FEVER; GASTROINTESTINAL HEMORRHAGE; GLUTAMINOLYSIS; GLYCOLYSIS; HEADACHE; HEMATURIA; HUMAN; HYPERESTHESIA; LETHARGY; LEUKOPENIA; LIVER TOXICITY; MANIA; MYALGIA; NEUROLOGIC DISEASE; ORAL MUCOSITIS; OTOTOXICITY; PARANOID SCHIZOPHRENIA; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHOTOPHOBIA; RASH; REVIEW; SCROTAL PAIN; THROMBOCYTOPENIA; UREMIA; CLINICAL TRIAL (TOPIC); METABOLISM; NEOPLASMS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; DIAZOOXONORLEUCINE; HUMANS; INDAZOLES; NEOPLASMS;

EID: 84942292107     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2015/690492     Document Type: Review

References (119)

1. J. F. Barger and D. R. Plas, "Balancing biosynthesis and bioenergetics: metabolic programs in oncogenesis, " Endocrine-Related Cancer, vol. 17, no. 4, pp. R287-R304, 2010.
2. A. P. Gomes and J. Blenis, "A nexus for cellular homeostasis: the interplay between metabolic and signal transduction pathways, " Current Opinion in Biotechnology, vol. 34, pp. 110-117, 2015.
3. A. Krejci, "Metabolic sensors and their interplay with cell signalling and transcription, " Biochemical Society Transactions, vol. 40, no. 2, pp. 311-323, 2012.
4. O. Warburg, F. Wind, and E. Negelein, "The metabolism of tumors in the body, " The Journal of General Physiology, vol. 8, no. 6, pp. 519-530, 1927.
5. C. Jose, N. Bellance, and R. Rossignol, "Choosing between glycolysis and oxidative phosphorylation: a tumors dilemma?" Biochimica et BiophysicaActa-Bioenergetics, vol. 1807, no. 6, pp. 552-561, 2011.
6. J. Bergstrm, P. Furst, L. O. Nore, and E. Vinnars, "Intracellular free amino acid concentration in humanmuscle tissue, " Journal of Applied Physiology, vol. 36, no. 6, pp. 693-697, 1974.
7. K. S. Kuhn, K. Schuhmann, P. Stehle, D. Darmaun, and P. Frst, "Determination of glutamine inmuscle protein facilitates accurate assessment of proteolysis and de novo synthesis-derived endogenous glutamine production, " The American Journal of Clinical Nutrition, vol. 70, no. 4, pp. 484-489, 1999.
8. P. J. Hanson and D. S. Parsons, "Metabolism and transport of glutamine and glucose in vascularly perfused small intestine rat, " Biochemical Journal, vol. 166, no. 3, pp. 509-519, 1977.
9. K. W. Lanks, "End products of glucose and glutamine metabolism by L929 cells, " The Journal of Biological Chemistry, vol. 262, no. 21, pp. 10093-10097, 1987.
10. E. A. Newsholme, B. Crabtree, and M. S. M. Ardawi, "Glutamine metabolism in lymphocytes: its biochemical, physiological and clinical importance, " Quarterly Journal of Experimental Physiology, vol. 70, no. 4, pp. 473-489, 1985.
11. R. J. DeBerardinis, A. Mancuso, E. Daikhin et al. , "Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis, " Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 49, pp. 19345-19350, 2007.
12. C. M. Metallo, P. A. Gameiro, E. L. Bell et al. , "Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia, " Nature, vol. 481, no. 7381, pp. 380-384, 2012.
13. H. Yoo, G. Stephanopoulos, and J. K. Kelleher, "Quantifying carbon sources for de novo lipogenesis in wild-type and IRS-1 knockout brown adipocytes, " The Journal of Biological Chemistry, vol. 45, no. 7, pp. 1324-1332, 2004.
14. M. Meng, S. Chen, T. Lao, D. Liang, and N. Sang, "Nitrogen anabolism underlies the importance of glutaminolysis in proliferating cells, " Cell Cycle, vol. 9, no. 19, pp. 3921-3932, 2010.
15. W. L. McKeehan, "Glycolysis, glutaminolysis and cell proliferation, " Cell Biology International Reports, vol. 6, no. 7, pp. 635-650, 1982.
16. M. Yuneva, N. Zamboni, P. Oefner, R. Sachidanandam, and Y. Lazebnik, "Deficiency in glutamine but not glucose induces MYC-dependent apoptosis in human cells, " The Journal of Cell Biology, vol. 178, no. 1, pp. 93-105, 2007.
17. H. Shim, Y. S. Chun, B. C. Lewis, and C. V. Dang, "A unique glucose-dependent apoptotic pathway induced by c-Myc, " Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 4, pp. 1511-1516, 1998.
18. A. J. Levine and A. M. Puzio-Kuter, "The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes, " Science, vol. 330, no. 6009, pp. 1340-1344, 2010.
19. C. V. Dang and G. L. Semenza, "Oncogenic alterations of metabolism, " Trends in Biochemical Sciences, vol. 24, no. 2, pp. 68-72, 1999.
20. S. J. Yeung, J. Pan, and M.-H. Lee, "Roles of p53, MYC and HIF-1 in regulating glycolysis-the seventh hallmark of cancer, " Cellular and Molecular Life Sciences, vol. 65, no. 24, pp. 3981-3999, 2008.
21. D. Gaglio, C. M. Metallo, P. A. Gameiroet al. , "OncogenicK-Ras decouples glucose and glutaminemetabolismto support cancer cell growth, " Molecular Systems Biology, vol. 7, article 523, 2011.
22. G. L. Semenza, "HIF-1 mediates metabolic responses to intratumoral hypoxia andoncogenicmutations, "The Journal of Clinical Investigation, vol. 123, no. 9, pp. 3664-3671, 2013.
23. B. Magnuson, B. Ekim, and D. C. Fingar, "Regulation and function of ribosomal protein S6 kinase (S6K) within mTOR signalling networks, " Biochemical Journal, vol. 441, no. 1, pp. 1-21, 2012.
24. C. C. Dibble and B. D. Manning, "Signal integration by mTORC1 coordinates nutrient input with biosynthetic output, " Nature Cell Biology, vol. 15, no. 6, pp. 555-564, 2013.
25. J. J. Howell, S. J. H. Ricoult, I. Ben-Sahra, and B. D. Manning, "A growing role for mTOR in promoting anabolic metabolism, " Biochemical Society Transactions, vol. 41, no. 4, pp. 906-912, 2013.
26. Y. Samuels and K. Ericson, "Oncogenic PI3K and its role in cancer, " Current Opinion in Oncology, vol. 18, no. 1, pp. 77-82, 2006.
27. H. Blker, B. Helmchen, A. Bnisch et al. , "Mutational activation of the RAS-RAF-MAPK and the wnt pathway in small intestinal adenocarcinomas, " Scandinavian Journal of Gastroenterology, vol. 39, no. 8, pp. 748-753, 2004.
28. P. R. Band, M. Deschamps, J. G. Besner, R. Leclaire, P. Gervais, and A. De Sanctis, "Phase I toxicologic study of lonidamine in cancer patients, " Oncology, vol. 41, supplement 1, pp. 56-59, 1984.
29. C. W. Young, V. E. Currie, J. H. Kim, M. A. OHehir, F. M. Farag, and J. E. Kinahan, "Phase I and clinical pharmacologic evaluation of lonidamine in patients with advanced cancer, " Oncology, vol. 41, no. 1, pp. 60-65, 1984.
30. H. I. Robins, W. L. Longo, R. K. Lagoni et al. , "Phase I trial of lonidaminewithwhole body hyperthermia in advanced cancer, " Cancer Research, vol. 48, no. 22, pp. 6587-6592, 1988.
31. H. Rosenfeld and J. Roberts, "Enhancement of antitumor activity of glutamine antagonists 6-diazo-5-oxo-L-norleucine and acivicin in cell culture by glutaminase-asparaginase, " Cancer Research, vol. 41, no. 4, pp. 1324-1328, 1981.
32. J. S. Kovach, R. T. Eagan, G. Powis, J. Rubin, E. T. Creagan, and C. G. Moertel, "Phase I and pharmacokinetic studies of DON, " Cancer Treatment Reports, vol. 65, no. 11-12, pp. 1031-1036, 1981.
33. A. Rahman, F. P. Smith, P.-V. T. Luc, and P. V. Wooley, "Phase I study and clinical pharmacology of 6-diazo-5-oxo-Lnorleucine (DON), " Investigational New Drugs, vol. 3, no. 4, pp. 369-374, 1985.
34. R. H. Earhart, J. M. Koeller, and H. L. Davis, "Phase I trial of 6-diazo-5-oxo-L-norleucine (DON) administered by 5-day courses, " Cancer Treatment Reports, vol. 66, no. 5, pp. 1215-1217, 1982.
35. M. P. Sullivan, J. A. Nelson, S. Feldman, and B. Van Nguyen, "Pharmacokinetic and phase I study of intravenous DON (6-diazo-5-oxo-L-norleucine) in children, " Cancer Chemotherapy and Pharmacology, vol. 21, no. 1, pp. 78-84, 1988.
36. C. Nistico, C. Garufi, M. Milella et al. , "Weekly epirubicin plus lonidamine in advanced breast carcinoma, " Breast Cancer Research and Treatment, vol. 56, no. 3, pp. 233-237, 1999.
37. M. Lopez, P. Vici, L. Di Lauro et al. , "Intrapatient comparison of single-agent epirubicin with or without lonidamine in metastatic breast cancer, " European Journal of Cancer, vol. 31, no. 10, pp. 1611-1614, 1995.
38. V. Gebbia, N. Borsellino, A. Testa et al. , "Cisplatin and epirubicin plus oral lonidamine as first-line treatment for metastatic breast cancer: a phase II study of the Southern Italy Oncology Group (GOIM), " Anti-Cancer Drugs, vol. 8, no. 10, pp. 943-948, 1997.
39. L. Dogliotti, S. Danese, A. Berruti et al. , "Cisplatin, epirubicin, and lonidamine combination regimen as first-line chemotherapy for metastatic: breast cancer: a pilot study, " Cancer Chemotherapy and Pharmacology, vol. 41, no. 4, pp. 333-338, 1998.
40. A. Contu, N. A. Olmeo, P. Pani, A. Deriu, S. Ortu, and C. Paga, "Lonidamine in non-small-cell lung cancer: a phase II study, " Tumori, vol. 77, no. 1, pp. 52-55, 1991.
41. P. Comella, G. Frasci, N. Panza et al. , "Cisplatin, gemcitabine, and vinorelbine combination therapy in advanced non-smallcell lung cancer: a phase II randomized Study of the Southern Italy Cooperative Oncology Group, " Journal of Clinical Oncology, vol. 17, no. 5, pp. 1526-1534, 1999.
42. L. Portalone, A. Lombardi, A. Antilli et al. , "Treatment of inoperable non-small cell lung carcinomastage IIIB and IVwith cisplatin, epidoxorubicin, vindesine and lonidamine: a phase II study, " Tumori, vol. 85, no. 4, pp. 239-242, 1999.
43. M. De Lena, V. Lorusso, A. Latorre et al. , "Paclitaxel, cisplatin and lonidamine in advanced ovarian cancer. A phase II study, " European Journal of Cancer, vol. 37, no. 3, pp. 364-368, 2001.
44. M. De Lena, V. Lorusso, C. Bottalico et al. , "Revertant and potentiating activity of lonidamine in patients with ovarian cancer previously treated with platinum, " Journal of Clinical Oncology, vol. 15, no. 10, pp. 3208-3213, 1997.
45. C. Bottalico, V. Lorusso, M. Brandi et al. , "Correlation between HPLC-determined lonidamine serum levels and clinical response in patients with advanced ovarian cancer, " Anticancer Research, vol. 16, no. 6, pp. 3865-3869, 1996.
46. A. Gadducci, I. Brunetti, M. P. Muttini et al. , "Epidoxorubicin and lonidamine in refractory or recurrent epithelial ovarian cancer, " European Journal of Cancer, vol. 30, no. 10, pp. 1432-1435, 1994.
47. L. Magno, F. Terraneo, and G. B. Ciottoli, "Lonidamine and radiotherapy in head and neck cancers. APilot Study, "Oncology, vol. 41, no. 1, pp. 113-115, 1984.
48. E. Colella, M. Merlano, F. Blengio et al. , "Randomised phase II study of methotrexate (MTX) versus methotrexate plus lonidamine (MTX + LND) in recurrent and/or metastatic carcinoma of the head and neck, " European Journal of Cancer, vol. 30, no. 7, pp. 928-930, 1994.
49. L. Magno, F. Terraneo, F. Bertoni et al. , "Double-blind randomized study of lonidamine and radiotherapy in head and neck cancer, " International Journal of Radiation Oncology, Biology, Physics, vol. 29, no. 1, pp. 45-55, 1994.
50. F. Calabresi, L. Di Lauro, P. Marolla et al. , "Fluorouracil, doxorubicin, and cyclophosphamide versus fluorouracil, doxorubicin, and cyclophosphamide plus lonidamine for the treatment of advanced breast cancer: a multicentric randomized clinical study, " Seminars in Oncology, vol. 18, no. 2, supplement 4, pp. 66-72, 1991.
51. D. Amadori, G. L. Frassineti, A. De Matteis et al. , "Modulating effect of lonidamine on response to doxorubicin in metastatic breast cancer patients: results from a multicenter prospective randomized trial, " Breast Cancer Research and Treatment, vol. 49, no. 3, pp. 209-217, 1998.
52. P. Pacini, M. Rinaldini, R. Algeri et al. , "FEC (5-fluorouracil, epidoxorubicin and cyclophosphamide) versus EM (epidoxorubicin and mitomycin-C) with or without lonidamine as first-line treatment for advanced breast cancer. A multicentric randomised study. Final results, " European Journal of Cancer, vol. 36, no. 8, pp. 966-975, 2000.
53. L. Dogliotti, A. Berruti, T. Buniva et al. , "Lonidamine significantly increases the activity of epirubicin in patients with advanced breast cancer: results from a multicenter prospective randomized trial, " Journal of Clinical Oncology, vol. 14, no. 4, pp. 1165-1172, 1996.
54. A. Berruti, R. Bitossi, G. Gorzegno et al. , "Time to progression in metastatic breast cancer patients treated with epirubicin is not improved by the addition of either cisplatin or lonidamine: final results of a phase III study with a factorial design, " Journal of Clinical Oncology, vol. 20, no. 20, pp. 4150-4159, 2002.
55. U. Gatzemeier, F. Cavalli, K. Hussinger et al. , "Phase III trial with and without lonidamine in non-small cell lung cancer, " Seminars in Oncology, vol. 18, no. 2, supplement 4, pp. 42-48, 1991.
56. G. P. Ianniello, G. De Cataldis, P. Comella et al. , "Cisplatin, epirubicin, and vindesine with or without lonidamine in the treatment of inoperable nonsmall cell lung carcinoma: a multicenter randomized clinical trial, " Cancer, vol. 78, no. 1, pp. 63-69, 1996.
57. G. Buccheri and D. Ferrigno, "A randomised trial of MACC chemotherapy with or without lonidamine in advanced nonsmall cell lung cancer, " European Journal of Cancer, vol. 30, no. 10, pp. 1424-1431, 1994.
58. F. De Marinis, M. Rinaldi, A. Ardizzoni et al. , "The role of vindesine and lonidamine in the treatment of elderly patients with advanced non-small cell lung cancer: a phase III randomized FONICAP trial. Italian Lung Cancer Task Force, " Tumori, vol. 85, no. 3, pp. 177-182, 1999.
59. C. W. Scarantino, A. J. McCunniff, G. Evans, C. W. Young, and D. A. Paggiarino, "A prospective randomized comparison of radiation therapy plus lonidamine versus radiation therapy plus placebo as initial treatment of clinically localized but nonresectable nonsmall cell lung cancer, " International Journal of Radiation Oncology, Biology, Physics, vol. 29, no. 5, pp. 999-1004, 1994.
60. R. T. Eagan, S. Frytak, W. C. Nichols, E. T. Creagan, and J. N. Ingle, "Phase II study of DON in patients with previously treated advanced lung cancer, " Cancer Treatment Reports, vol. 66, no. 8, pp. 1665-1666, 1982.
61. J. Rubin, S. Sorensen, A. J. Schutt et al. , "A phase II study of 6-diazo-5-oxo-L-norleucine (DON, NSC-7365) in advanced large bowel carcinoma, " American Journal of Clinical Oncology, vol. 6, no. 3, pp. 325-326, 1983.
62. G. Lynch, N. Kemeny, and E. Casper, "Phase II evaluation of DON (6-Diazo-5-Oxo-L-Norleucine) in patients with advanced colorectal carcinoma, " American Journal of Clinical Oncology, vol. 5, no. 5, pp. 541-543, 1982.
63. R. H. Earhart, D. J. Amato, A. Yuang-Chi Chang et al. , "Phase II trial of 6-diazo-5-oxo-L-norleucine versus aclacinomycin-A in advanced sarcomas and mesotheliomas, " Investigational New Drugs, vol. 8, no. 1, pp. 113-119, 1990.
64. C. Mueller, S. Al-Batran, E. Jaeger et al. , "A phase II study of PEGylated glutaminase (PEG-PGA) plus 6-diazo-5-oxo-Lnorleucine (DON) in patients with advanced refractory solid tumors, " Journal of Clinical Oncology, vol. 26, no. 15S, abstract 2533, 2008, ASCO Annual Meeting.
65. S. Ganapathy-Kanniappan and J.-F. H. Geschwind, "Tumor glycolysis as a target for cancer therapy: progress and prospects, " Molecular Cancer, vol. 12, article 152, 2013.
66. C. Granchi and F. Minutolo, "Anticancer agents that counteract tumor glycolysis, " ChemMedChem, vol. 7, no. 8, pp. 1318-1350, 2012.
67. R. Catane, D. D. von Hoff, D. L. Glaubiger, and F. M. Muggia, "Azaserine, DON, and azotomycin: three diazo analogs of Lglutamine with clinical antitumor activity, " Cancer Treatment Reports, vol. 63, no. 6, pp. 1033-1038, 1979.
68. N. Prajda, "Enzyme targets of antiglutamine agents in cancer chemotherapy, " Advances in Enzyme Regulation, vol. 24, pp. 207-223, 1985.
69. A. G. Thomas, C. Rojas, C. Tanega et al. , "Kinetic characterization of ebselen, chelerythrine and apomorphine as glutaminase inhibitors, " Biochemical and Biophysical Research Communications, vol. 438, no. 2, pp. 243-248, 2013.
70. M. I. Gross, S. D. Demo, J. B. Dennisonet al. , "Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer, " Molecular Cancer Therapeutics, vol. 13, no. 4, pp. 890-901, 2014.
71. B. Silvestrini, C. DeMartino, V. Cioli et al. , "Antispermatogenic activity of diclondazolic acid in rats, " in Recent Progress in Andrology, A. Fabbrini and E. Steinberger, Eds. , pp. 453-457, Academic Press, New York, NY, USA, 1978.
72. A. Floridi, M. G. Paggi, M. L. Marcante, B. Silvestrini, A. Caputo, and C. deMartino, "Lonidamine, a selective inhibitor of aerobic glycolysis ofmurine tumor cells, " Journal of the National Cancer Institute, vol. 66, no. 3, pp. 497-499, 1981.
73. A. Floridi, M. G. Paggi, S. DAtri et al. , "Effect of lonidamine on the energy metabolism of Ehrlich ascites tumor cells, " Cancer Research, vol. 41, no. 11, pp. 4661-4666, 1981.
74. R. N. Sadeghi, F. Karami-Tehrani, and S. Salami, "Targeting prostate cancer cell metabolism: impact of hexokinase andCPT-1 enzymes, " Tumor Biology, vol. 36, no. 4, pp. 2893-2905, 2015.
75. M. G. Paggi, C. M. Carapella, M. Fanciulli et al. , "Effect of lonidamine on human malignant gliomas: biochemical studies, " Journal of Neuro-Oncology, vol. 6, no. 3, pp. 203-209, 1988.
76. H. Ben-Horin, M. Tassini, A. Vivi, G. Navon, and O. Kaplan, "Mechanism of action of the antineoplastic drug lonidamine: 31P and 13C nuclear magnetic resonance studies, " Cancer Research, vol. 55, no. 13, pp. 2814-2821, 1995.
77. O. Ben-Yoseph, J. C. Lyons, C. W. Song, and B. D. Ross, "Mechanism of action of lonidamine in the 9L brain tumor model involves inhibition of lactate efflux and intracellular acidification, " Journal of Neuro-Oncology, vol. 36, no. 2, pp. 149-157, 1998.
78. O. Sordet, C. Rb, I. Leroy et al. , "Mitochondria-targeting drugs arsenic trioxide and lonidamine bypass the resistance of TPA-differentiated leukemic cells to apoptosis, " Blood, vol. 97, no. 12, pp. 3931-3940, 2001.
79. A. Biroccio, D. Del Bufalo, M. Fanciulli, T. Bruno, G. Zupi, and A. Floridi, "bcl-2 inhibits mitochondrial metabolism and lonidamine-induced apoptosis in adriamycin-resistant MCF7 cells, " International Journal of Cancer, vol. 82, no. 1, pp. 125-130, 1999.
80. L. Orlandi, N. Zaffaroni, A. Bearzatto, R. Villa, C. DeMarco, and R. Silvestrini, "Lonidamine as a modulator of taxol activity in human ovarian cancer cells: effects on cell cycle and induction of apoptosis, " International Journal of Cancer, vol. 78, no. 3, pp. 377-384, 1998.
81. L. Ravagnan, I. Marzo, P. Costantini et al. , "Lonidamine triggers apoptosis via a direct, Bcl-2-inhibited effect on the mitochondrial permeability transition pore, " Oncogene, vol. 18, no. 16, pp. 2537-2546, 1999.
82. A.-S. Belzacq, C. E. Hamel, H. L. A. Vieira et al. , "Adenine nucleotide translocator mediates the mitochondrial membrane permeabilization induced by lonidamine, arsenite and CD437, " Oncogene, vol. 20, no. 52, pp. 7579-7587, 2001.
83. L. Galluzzi, O. Kepp, N. Tajeddine, andG. Kroemer, "Disruption of the hexokinase-VDAC complex for tumor therapy, " Oncogene, vol. 27, no. 34, pp. 4633-4635, 2008.
84. N. Goldin, L. Arzoine, A. Heyfets et al. , "Methyl jasmonate binds to and detaches mitochondria-bound hexokinase, " Oncogene, vol. 27, no. 34, pp. 4636-4643, 2008.
85. J. G. Besner, R. Leclaire, P. R. Band, M. Deschamps, A. J. De Sanctis, and B. Catanese, "Pharmacokinetics of lonidamine after oral administration in cancer patients, " Oncology, vol. 41, supplement 1, pp. 48-52, 1984.
86. D. R. Newell, J. Mansi, and J. Hardy, "The pharmacokinetics of oral lonidamine in breast cancer and lung cancer patients, " Seminars in Oncology, vol. 18, no. 2, pp. 11-17, 1991.
87. J. L. Mansi, A. de Graeff, D. R. Newell et al. , "A phase II clinical and pharmacokinetic study of lonidamine in patients with advanced breast cancer, " British Journal of Cancer, vol. 64, no. 3, pp. 593-597, 1991.
88. G. R. della Cuna and P. Pedrazzoli, "Toxicity and clinical tolerance of lonidamine, " Seminars in Oncology, vol. 18, no. 2, supplement 4, pp. 18-22, 1991.
89. H. W. Dion, S. A. Fusari, Z. L. Jakubowski, J. G. Zora, and Q. R. Bartz, "6-Diazo-5-oxo-L-norleucine, a newtumor-inhibitory substance. II. Isolation and characterization, " Journal of the American Chemical Society, vol. 78, no. 13, pp. 3075-3077, 1956.
90. L. M. Pinkus, "Glutamine binding sites, " Methods in Enzymology, vol. 46, no. C, pp. 414-427, 1977.
91. M. L. Eidinoff, J. E. Knoll, B. Marano et al. , "Pyrimidine studies I. Effect ofDON(6-diazo-5oxo-L-norleucine) on incorporation of precursors into nucleic acid pyrimidines, " Cancer Research, vol. 18, pp. 105-109, 1958.
92. B. Levenberg, I. Melnick, and J. M. Buchanan, "Biosynthesis of the purines, XV. The effect of Aza-L-Serine and 6-Diazo-5-Oxo-L-Norleucine on inosinic acid biosynthesis de novo, " The Journal of Biological Chemistry, vol. 225, no. 1, pp. 163-176, 1957.
93. G. S. Ahluwalia, J. L. Grem, Z. Hao, and D. A. Cooney, "Metabolism and action of amino acid analog anti-cancer agents, " Pharmacology andTherapeutics, vol. 46, no. 2, pp. 243-271, 1990.
94. R. K. Barclay and M. A. Phillipps, "Effects of 6-diazo-5-oxolnorleucine and other tumor inhibitors on the biosynthesis of nicotinamide adenine dinucleotide in mice, " Cancer Research, vol. 26, no. 2, pp. 282-286, 1966.
95. R. J. Rosenbluth, D. A. Cooney, H. N. Jayaram, H. A. Milman, and E. R. Homan, "DON, CONVandDONV-II. Inhibition of Lasparagine synthetase in vivo, " Biochemical Pharmacology, vol. 25, no. 16, pp. 1851-1858, 1976.
96. G. L. Coffey, J. Ehrlich, M. W. Fisher et al. , "6-Diazo-5-oxo-L-norleucine, a new tumor-inhibitory substance. I. Biologic studies, " Antibiotics and Chemotherapy, vol. 6, no. 8, pp. 487-497, 1956.
97. J. C. Aledo, P. M. Gmez-Fabre, L. Olalla, and J. Mrquez, "Identification of two human glutaminase loci and tissue-specific expression of the two related genes, " Mammalian Genome, vol. 11, no. 12, pp. 1107-1110, 2000.
98. K. Thangavelu, Q. Y. Chong, B. C. Low, and J. Sivaraman, "Structural basis for the active site inhibition mechanism of human kidney-type glutaminase (KGA), " Scientific Reports, vol. 4, article 3827, 2014.
99. G. S. Tarnowski and C. C. Stock, "Effects of combinations of azaserine and of 6-diazo-5-oxo-L-norleucine with purine analogs and other antimetabolites on the growth of two mouse mammary carcinomas, " Cancer Research, vol. 17, no. 10, pp. 1033-1039, 1957.
100. A. A. Ovejera, D. P. Houchens, R. Catane, M. A. Sheridan, and F. M. Muggia, "Efficacy of 6-diazo-5-oxo-l-norleucine and N-[N-γ-glutamyl-6-diazo-5-oxo-norleucinyl]-6-diazo-5-oxonorleucine against experimental tumors in conventional and nude mice, " Cancer Research, vol. 39, no. 8, pp. 3220-3224, 1979.
101. G. Dranoff, G. B. Elion, H. S. Friedman, and D. D. Bigner, "Combination chemotherapy in vitro exploiting glutamine metabolism of human glioma and medulloblastoma, " Cancer Research, vol. 45, no. 9, pp. 4082-4086, 1985.
102. K. R. Huber, E. P. Mayer, D. F. Mitchell, and J. Roberts, "Cell cycle phase perturbations by 6-diazo-5-oxo-L-norleucine and acivicin in normal and neoplastic human cell lines, " British Journal of Cancer, vol. 55, no. 6, pp. 653-656, 1987.
103. F. Wu, A. Lukinius, M. Bergstrm, B. Eriksson, Y. Watanabe, and B. Langstrm, "A mechanism behind the antitumour effect of 6-diazo-5-oxo-L-norleucine (DON): disruption of mitochondria, " European Journal of Cancer, vol. 35, no. 7, pp. 1155-1161, 1999.
104. F. Wu, M. Bergstrm, M. Stridsberg et al. , "Effect of 6-diazo-5-oxo-L-norleucine (DON) on human carcinoid tumor cell aggregates, " Anticancer Research, vol. 17, no. 4 A, pp. 2363-2367, 1997.
105. R. R. Olsen, M. N. Mary-Sinclair, Z. Yin, and K. W. Freeman, "Antagonizing BCL-2 family members sensitizes neuroblastoma and Ewings sarcoma to an inhibitor of glutamine metabolism, " PLoS ONE, vol. 10, no. 1, Article IDe0116998, 2015.
106. L. M. Shelton, L. C. Huysentruyt, andT. N. Seyfried, "Glutamine targeting inhibits systemic metastasis in the VM-M3 murine tumor model, " International Journal of Cancer, vol. 127, no. 10, pp. 2478-2485, 2010.
107. S. Ghosh, S. Roy, M. Banerjee, and P. Maity, "Modulation of tumor induced angiogenesis in Ehrlich ascites tumor, " Journal of Experimental and Clinical Cancer Research, vol. 23, no. 4, pp. 681-690, 2004.
108. R. B. Sklaroff, E. S. Casper, G. B. Magill, and C. W. Young, "Phase I study of 6-diazo-5-oxo-L-norleucine (DON), " Cancer Treatment Reports, vol. 64, no. 12, pp. 1247-1251, 1980.
109. J. Alt, M. C. Potter, C. Rojas, and B. S. Slusher, "Bioanalysis of 6-diazo-5-oxo-L-norleucine in plasma and brain by ultraperformance liquid chromatography mass spectrometry, " Analytical Biochemistry, vol. 474, pp. 28-34, 2015.
110. J. H. M. Yeo, J. C. Y. Lo, P. M. Nissom, and V. V. T. Wong, "Glutamine or glucose starvation in hybridoma cultures induces death receptor and mitochondrial apoptotic pathways, " Biotechnology Letters, vol. 28, no. 18, pp. 1445-1452, 2006.
111. L. Fitzpatrick, H. A. Jenkins, and M. Butler, "Glucose and glutamine metabolism of a murine B-lymphocyte hybridoma grown in batch culture, " Applied Biochemistry and Biotechnology, vol. 43, no. 2, pp. 93-116, 1993.
112. B. Li and M. C. Simon, "Molecular pathways: targeting MYCinduced metabolic reprogramming and oncogenic stress in cancer, " Clinical Cancer Research, vol. 19, no. 21, pp. 5835-5841, 2013.
113. Y. Chendong, J. Sudderth, D. Tuyen, R. G. Bachoo, J. G. McDonald, and R. J. DeBerardinis, "Glioblastoma cells require glutamate dehydrogenase to survive impairments of glucose metabolism or Akt signaling, " Cancer Research, vol. 69, no. 20, pp. 7986-7993, 2009.
114. H. Wu, Z. Li, P. Yang, L. Zhang, Y. Fan, and Z. Li, "PKM2 depletion induces the compensation of glutaminolysis through β-catenin/c-Myc pathway in tumor cells, " Cellular Signalling, vol. 26, no. 11, pp. 2397-2405, 2014.
115. T. Pan, L. Gao, G. Wu et al. , "Elevated expression of glutaminase confers glucose utilization via glutaminolysis in prostate cancer, " Biochemical and Biophysical Research Communications, vol. 456, no. 1, pp. 452-458, 2015.
116. M. C. B. Tan, D. C. Linehan, W. G. Hawkins, B. A. Siegel, and S. M. Strasberg, "Chemotherapy-induced normalization of FDG uptake by colorectal liver metastases does not usually indicate complete pathologic response, " Journal of Gastrointestinal Surgery, vol. 11, no. 9, pp. 1112-1119, 2007.
117. M. Griffiths, D. Keast, G. Patrick, M. Crawford, and T. N. Palmer, "The role of glutamine and glucose analogues in metabolic inhibition of human myeloid leukaemia in vitro, " International Journal of Biochemistry, vol. 25, no. 12, pp. 1749-1755, 1988.
118. D. Cervantes-Madrid and A. Duenas-Gonzlez, "Antitumor effects of a drug combination targeting glycolysis, glutaminolysis and de novo synthesis of fatty acids, " Oncology Reports, vol. 34, no. 3, pp. 1533-1542, 2015.
119. A. Sobrero and P. Bruzzi, "Incremental advance or seismic shift? The need to raise the bar of efficacy for drug approval, " Journal of Clinical Oncology, vol. 27, no. 35, pp. 5868-5873, 2009.